Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer

This study has been terminated.
(Study was terminated due to slow subject accrual)
Sponsor:
Collaborator:
AstraZeneca
Information provided by (Responsible Party):
Lyudmila Bazhenova, M.D., University of California, San Diego
ClinicalTrials.gov Identifier:
NCT00592007
First received: December 26, 2007
Last updated: July 12, 2012
Last verified: July 2012
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: July 2012
  Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)